about
Accelerating tuberculosis vaccine trials with diagnostic and prognostic biomarkers.Tuberculosis innovations mean little if they cannot save livesImmunological consequences of strain variation within the Mycobacterium tuberculosis complex.The paradigm shift to end tuberculosis. Are we ready to assume the changes?An Integrated Workflow To Assess Technical and Biological Variability of Cell Population Frequencies in Human Peripheral Blood by Flow Cytometry.Advances in Drug Discovery of New Antitubercular Multidrug-Resistant Compounds.Striking the right immunological balance prevents progression of tuberculosis.Non-Steroidal Anti-inflammatory Drugs As Host-Directed Therapy for Tuberculosis: A Systematic Review.Disseminated tuberculosis among hospitalised HIV patients in South Africa: a common condition that can be rapidly diagnosed using urine-based assays.Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections.Experimental study of tuberculosis: From animal models to complex cell systems and organoids.Differential Recognition of Mycobacterium tuberculosis-Specific Epitopes as a Function of Tuberculosis Disease History.The association between Bacillus Calmette-Guérin vaccination (1331 SSI) skin reaction and subsequent scar development in infants.Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis.How Can Elispot Add Information to Improve Knowledge on Tropical Diseases?Evaluation of minor groove binders (MGBs) as novel anti-mycobacterial agents and the effect of using non-ionic surfactant vesicles as a delivery system to improve their efficacy.Horizontal acquisition of a hypoxia-responsive molybdenum cofactor biosynthesis pathway contributed to Mycobacterium tuberculosis pathoadaptation.Targeting DNA Replication and Repair for the Development of Novel Therapeutics against Tuberculosis.Estimating the impact of tuberculosis anatomical classification on treatment outcomes: A patient and surveillance perspective analysis.Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine.New antituberculous drugs derived from natural products: current perspectives and issues in antituberculous drug development.Tuberculosis in the Mediterranean Region
P2860
Q30403003-469A2B52-F873-4ECF-BB5E-B4287D1BABC6Q33627409-776A51EF-E99F-4614-A6A5-44E90AB642DDQ37717814-C10AA814-884B-433F-89AA-85218ADFFB69Q38676708-C191155F-7F1C-4EE3-B95C-04CC8B6588AFQ39030586-85EB64A3-8433-4ED1-9BD6-01E2BBF1DDA5Q39354581-2F853625-6076-4B1C-8607-959C92660891Q39437320-9E6AA532-5CDC-4641-8E5A-7C47AA0D4172Q39437994-38A8A5F0-F506-453D-B012-2574A7478E5CQ40061579-C23F6F38-7B46-4B37-AE4D-944B739B477DQ40068511-D8B711CE-244C-4441-B814-56FBCBC5D908Q40089850-AD67C304-F363-4A07-AE08-16A85B74E680Q40101402-9A167CE5-F42A-44F4-82F3-77E5EF26B963Q40107894-CE742384-D505-431B-864D-B1D136960E9CQ41717866-AB720193-3E36-402D-9FED-7CA9410B9346Q41928044-0D0BEA9E-7B74-476E-9370-18925E70433FQ41992950-7C2EDFDC-D39E-4926-8511-449420414DB0Q46253988-A972B885-8F08-4A92-8527-E627FFD0C0BAQ46478240-7894F8A9-2B73-4554-900E-6E0860F6069BQ47096786-3AC65AD6-B3E0-4EAD-8011-17AAE6406FABQ47553632-B65BAF08-233F-4D81-9747-05D4349E1C05Q47594312-9DF67D77-72B7-481D-9A28-2774A2F28418Q59325841-93C9AE1E-A2FF-4D7D-B620-C9AB351385B3
P2860
description
scientific article published on 27 October 2016
@en
наукова стаття, опублікована в жовтні 2016
@uk
name
Tuberculosis
@en
type
label
Tuberculosis
@en
prefLabel
Tuberculosis
@en
P2093
P2860
P50
P356
P1476
Tuberculosis
@en
P2093
Ann Ginsberg
Catharina C Boehme
David Dowdy
Haileyesus Getahun
Keertan Dheda
Marcel A Behr
Maziar Divangahi
Melvin Spigelman
Soumya Swaminathan
P2860
P2888
P356
10.1038/NRDP.2016.76
P577
2016-10-27T00:00:00Z